776 related articles for article (PubMed ID: 31258135)
1. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
Kaya E; Yılmaz Y
Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
[TBL] [Abstract][Full Text] [Related]
2. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
3. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
5. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease - A global public health perspective.
Younossi ZM
J Hepatol; 2019 Mar; 70(3):531-544. PubMed ID: 30414863
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease burden: Australia, 2019-2030.
Adams LA; Roberts SK; Strasser SI; Mahady SE; Powell E; Estes C; Razavi H; George J
J Gastroenterol Hepatol; 2020 Sep; 35(9):1628-1635. PubMed ID: 32048317
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
[No Abstract] [Full Text] [Related]
11. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
13. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
15. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
[TBL] [Abstract][Full Text] [Related]
16. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
18. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
Vernon G; Baranova A; Younossi ZM
Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
[TBL] [Abstract][Full Text] [Related]
20. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]